Goldman Sachs Reinitiates Buy on RVMD with $267 Target Amid Biot

Revolution Medicines (RVMD) received FDA Breakthrough Therapy designation for its drug RASONQUE. The article discusses analyst projections and long-term expectations for the company, based on historical data and forecasts. Simply Wall St notes it does not provide financial advice and has no position in RVMD.

Revolution Medicines (RVMD) received FDA Breakthrough Therapy Designation for RASONQUE in combination with other drugs for metastatic pancreatic cancer. The company was also added to the FTSE All World Index. Management expects $1.6B-$1.7B in operating expenses by 2026 with no current revenue. Analysts project $3.5B in revenue and $411.3M in earnings by 2029, requiring significant earnings improvement.

Revolution Medicines COO Margaret Horn sold 4,967 shares worth $989,612 under a 10b5-1 plan. Shares were sold at $195.01-$199.30, with Horn retaining 149,680 shares. RVMD stock is up 322% in a year, trading at $190.95 with a $42.21B market cap. Analysts raised price targets after FDA approval of Rasonque, with targets ranging from $265 to $280.

Revolution Medicines (RVMD) saw a 340% stock increase over the past year, driven by clinical progress. The company recently received approval for RASONQUE, a treatment for pancreatic cancer, which showed a median overall survival of 13.2 months in trials. Analysts project potential revenue of $15.1 billion by 2034 for pancreatic cancer and $20.8 billion at peak, but the stock's current valuation may limit upside.

Parnassus Growth Equity Fund's Q2 2026 letter reported a 17.49% return, outperforming the Russell 1000 Growth Index. The fund added Revolution Medicines (RVMD), a clinical-stage oncology company, noting its promising drug, daraxonrasib, for pancreatic cancer. RVMD's stock price was $204.86, with a 358% gain over 52 weeks and a $43.91B market cap.

FDA approved Revolution Medicines' (RVMD) Rasonque for metastatic pancreatic cancer, nearly doubling survival in trials. The drug, priced at $39,800 for a 30-day supply, is the first broad RAS-targeted treatment. Revolution expects $28M in U.S. sales by Q3 2026, with $3.9B in cash for commercialization. Over 2,000 patients had access pre-approval.